Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 7229-7241
Publisher
Informa UK Limited
Online
2020-07-27
DOI
10.2147/ott.s255491
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
- (2020) Jackson G. Egen et al. IMMUNITY
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
- (2020) Robert Jotte et al. Journal of Thoracic Oncology
- Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
- (2020) Lucas A Horn et al. Journal for ImmunoTherapy of Cancer
- Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
- (2020) Kai Chen et al. LIFE SCIENCES
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
- (2019) Shweta Joshi et al. Journal of Oncology
- Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer
- (2019) Ping Fan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
- (2019) Ke Ma et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
- (2019) Min-Wei Yang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments
- (2019) Anusha Pusuluri et al. JOURNAL OF CONTROLLED RELEASE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
- (2019) Yang Liu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Immune checkpoint blockade therapy
- (2018) Thomas Wieder et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer
- (2018) L. Fehrenbacher et al. Journal of Thoracic Oncology
- Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC
- (2018) Scott Gettinger et al. Journal of Thoracic Oncology
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer secretome and inflammation: The bright and the dark sides of NF-κB
- (2018) Daria Capece et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Two-Step Senescence-Focused Cancer Therapies
- (2018) Cynthia J. Sieben et al. TRENDS IN CELL BIOLOGY
- The inducers of immunogenic cell death for tumor immunotherapy
- (2018) Xiuying Li TUMORI
- Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway
- (2018) Xuerong Sun et al. Cell Death & Disease
- The inducers of immunogenic cell death for tumor immunotherapy
- (2018) Xiuying Li TUMORI JOURNAL
- Pembrolizumab plus Chemotherapy in Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
- (2018) Peixin Dong et al. Frontiers in Oncology
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy
- (2018) Xiuwen Guan et al. JOURNAL OF CONTROLLED RELEASE
- Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy
- (2018) Hans-Gustaf Ljunggren et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
- (2018) Yaxiong Zhang et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
- (2018) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- PD-1 and cancer: molecular mechanisms and polymorphisms
- (2017) Arash Salmaninejad et al. IMMUNOGENETICS
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- Upregulation of Wnt signaling under hypoxia promotes lung cancer progression
- (2017) Chun-Fu Hong et al. ONCOLOGY REPORTS
- Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
- (2017) Keita Aoto et al. ONCOLOGY REPORTS
- Role of vascular normalization in benefit from metronomic chemotherapy
- (2017) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
- (2017) Linda Tran et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression
- (2016) Tobias Eggert et al. CANCER CELL
- Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
- (2016) E. Beyranvand Nejad et al. CANCER RESEARCH
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Scientific Advances in Lung Cancer 2015
- (2016) Anne S. Tsao et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- CXCR4–CXCL12–CXCR7, TLR2–TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients
- (2016) Crescenzo D'Alterio et al. OncoImmunology
- Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer
- (2015) Tian Tian et al. Cancer Biomarkers
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Natural killer cells: The journey from puzzles in biology to treatment of cancer
- (2015) Lakshmi Narendra Bodduluru et al. CANCER LETTERS
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
- (2014) Y.-C. Lu et al. CLINICAL CANCER RESEARCH
- Chemoimmunotherapy: reengineering tumor immunity
- (2013) Gang Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing
- (2012) Sofia R. Gameiro et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Calreticulin in the immune system: ins and outs
- (2012) Malini Raghavan et al. TRENDS IN IMMUNOLOGY
- An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
- (2012) Laura Senovilla et al. OncoImmunology
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy
- (2009) S. J. Priceman et al. BLOOD
- Calreticulin: non-endoplasmic reticulum functions in physiology and disease
- (2009) Leslie I. Gold et al. FASEB JOURNAL
- Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
- (2009) G. V. Shurin et al. JOURNAL OF IMMUNOLOGY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started